CYNATA THERAPEUTICS LIMITEDCYNATA THERAPEUTICS LIMITEDCYNATA THERAPEUTICS LIMITED

CYNATA THERAPEUTICS LIMITED

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪47.30 M‬AUD
−0.055AUD
‪−9.74 M‬AUD
0.00AUD
‪193.71 M‬
Beta (1Y)
−0.95

About CYNATA THERAPEUTICS LIMITED


CEO
Kilian Kelly
Website
Headquarters
Cremorne
Founded
2003
ISIN
AU000000CYP7
FIGI
BBG000TKBTN2
Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. It focuses on proprietary mesenchymal stem cell technology. The company was founded on March 12, 2003 and is headquartered in Carlton, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CYP is 0.220 AUD — it has increased by 4.76% in the past 24 hours. Watch CYNATA THERAPEUTICS LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange CYNATA THERAPEUTICS LIMITED stocks are traded under the ticker CYP.
CYP stock has risen by 4.76% compared to the previous week, the month change is a 2.33% rise, over the last year CYNATA THERAPEUTICS LIMITED has showed a 76.00% increase.
We've gathered analysts' opinions on CYNATA THERAPEUTICS LIMITED future price: according to them, CYP price has a max estimate of 0.83 AUD and a min estimate of 0.67 AUD. Watch CYP chart and read a more detailed CYNATA THERAPEUTICS LIMITED stock forecast: see what analysts think of CYNATA THERAPEUTICS LIMITED and suggest that you do with its stocks.
CYP reached its all-time high on Jul 26, 2019 with the price of 1.865 AUD, and its all-time low was 0.105 AUD and was reached on Jul 4, 2023. View more price dynamics on CYP chart.
See other stocks reaching their highest and lowest prices.
CYP stock is 7.14% volatile and has beta coefficient of −0.95. Track CYNATA THERAPEUTICS LIMITED stock price on the chart and check out the list of the most volatile stocks — is CYNATA THERAPEUTICS LIMITED there?
Today CYNATA THERAPEUTICS LIMITED has the market capitalization of ‪47.30 M‬, it has increased by 20.00% over the last week.
Yes, you can track CYNATA THERAPEUTICS LIMITED financials in yearly and quarterly reports right on TradingView.
CYNATA THERAPEUTICS LIMITED is going to release the next earnings report on Feb 20, 2025. Keep track of upcoming events with our Earnings Calendar.
CYP net income for the last half-year is ‪−5.20 M‬ AUD, while the previous report showed ‪−4.54 M‬ AUD of net income which accounts for −14.59% change. Track more CYNATA THERAPEUTICS LIMITED financial stats to get the full picture.
No, CYP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CYP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CYNATA THERAPEUTICS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CYNATA THERAPEUTICS LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CYNATA THERAPEUTICS LIMITED stock shows the sell signal. See more of CYNATA THERAPEUTICS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.